

## Clinical Policy: Helicobacter Pylori Serology Testing

Reference Number: WNC.CP.142

Last Review Date: 08/24

Coding Implications

Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

**Note:** When state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

---

### Description

*Helicobacter pylori* (*H. pylori*) is the most prevalent chronic bacterial infection and is associated with peptic ulcer disease, chronic gastritis, gastric adenocarcinoma, and gastric mucosa associated lymphoid tissue (MALT) lymphoma. Noninvasive tests for the diagnosis of *H. pylori* include urea breath testing (UBT), stool antigen testing, and serology.<sup>1</sup>

### Policy/Criteria

- I. It is the policy of WellCare of North Carolina® that *H. pylori* serology testing is **not medically necessary** for diagnosing infection or evaluating treatment effectiveness.

### Background

The most common causes of peptic ulcer disease (PUD) are *H. pylori* infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs). *H. pylori* infection causes progressive functional and structural gastroduodenal damage.<sup>4</sup> Accurate diagnosis of *H. pylori* infection is a crucial part in the effective management of many gastroduodenal diseases. Several invasive and non-invasive diagnostic tests are available for the detection of *H. pylori* and each test has its usefulness and limitations in different clinical situations.<sup>8</sup>

Urea breath tests and stool antigen tests are the most widely used non-invasive tests for identifying *H. pylori* infection, as well as most accurate. In addition, they can be used to confirm cure. Serologic tests are a convenient but less accurate alternative and cannot be used to confirm cure.<sup>2</sup>

The urea breath test is the noninvasive test of choice for the diagnosis of *H. pylori*, with high sensitivity (88% to 95%) and specificity (95% to 100%) for the detection of active *H. pylori* infections.<sup>1,4</sup> Urea breath tests require the ingestion of urea labeled with the nonradioactive isotope carbon 13 or carbon 14. Specificity and sensitivity approach 100%. Urea breath testing is an option for test of cure and should be performed four to six weeks after completion of eradication therapy. Proton pump inhibitors (PPIs) must be stopped for at least two weeks before the test, and accuracy is lower in patients who have had distal gastrectomy.<sup>2</sup>

## CLINICAL POLICY WNC.CP.142

### HELICOBACTER PYLORI SEROLOGY TESTING



Stool antigen tests using monoclonal antibodies are as accurate as urea breath tests if a validated laboratory-based monoclonal test is used. Like urea breath tests, stool antigen tests detect only active infection and can also be used as a test of cure. PPIs should be stopped for two weeks before testing, but stool antigen tests are not as affected by PPI use.<sup>2</sup>

Serologic antibody testing detects immunoglobulin G specific to *H. pylori* in serum and cannot distinguish between an active infection and a past infection.<sup>2</sup> Most common serologic tests are based on an enzyme-linked immunosorbent assay (ELISA) technology. As with any test, prevalence of the *H. pylori* infection and the pretest probability influence the positive or negative predictive values. Overall, where the prevalence of *H. pylori* infection and the pretest probability are low, the negative predictive value of a serologic test is high whereas false positives are more frequent, with the opposite in high prevalence/high pretest probability cases (i.e., the positive predictive value is high but there is increased prevalence of false negative results).<sup>4</sup> Antibody testing cannot be used as a test of cure.<sup>2</sup>

#### *American Society for Clinical Pathology*

Per the American Society for Clinical Pathology, Serologic evaluation of patients to determine the presence/absence of *H. pylori* infection is no longer considered clinically useful. Alternative noninvasive testing methods (e.g., the urea breath test and stool antigen test) exist for detecting the presence of the bacteria and have demonstrated higher clinical utility, sensitivity, and specificity.<sup>11</sup>

#### *The American Gastroenterological Association (AGA)*

The AGA no longer recommends serology-based testing for diagnosing infection or evaluating treatment effectiveness as it is unable to distinguish between active infection and previous exposure to *H. pylori*, does not confirm eradication and has a poor positive predictive value when compared to active infection tests such as the urea breath test or stool antigen test.<sup>7</sup>

#### *The American College of Gastroenterology*

The American College of Gastroenterology states that all patients with active PUD, a past history of PUD (unless previous cure of *H. pylori* infection has been documented), low-grade gastric MALT lymphoma, or a history of endoscopic resection of early gastric cancer should be tested for *H. pylori* infection. In patients with uninvestigated dyspepsia who are under the age of 60 years and without alarm features, non-endoscopic testing for *H. pylori* infection is a consideration. Other indications to test patients for *H. pylori* infection may include, patients taking long-term low-dose aspirin, patients initiating chronic treatment with an NSAID, patients with unexplained iron deficiency anemia despite an appropriate evaluation and adults with idiopathic thrombocytopenic purpura. Any individual who tests positive should be offered eradication therapy. Patients with a history of PUD who have previously been treated for *H. pylori* infection should undergo eradication testing with a urea breath test or fecal antigen test.<sup>3</sup>

### **Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2024, American Medical Association. All rights reserved. CPT codes and CPT descriptions are

# CLINICAL POLICY WNC.CP.142

## HELICOBACTER PYLORI SEROLOGY TESTING



from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT®* Codes	Description
86677	Antibody; Helicobacter pylori

Reviews, Revisions, and Approvals	Reviewed Date	Approval Date
Original approval date	03/21	05/21
Reviewed CPT code.	10/21	02/22
Annual review. CPT code reviewed.	11/22	11/22
NCHC verbiage removed from NC Guidance Verbiage.	04/23	04/23
Annual Review. CPT code reviewed. Background updated and minor rewording with no clinical significance. References reviewed and updated.	08/23	08/23
Annual Review. References updated. Removed HCPCS and ICD-10 code boxes.	08/24	08/24

### References

1. Lamont JT. Indications and diagnostic tests for Helicobacter pylori infection in adults. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated July 13, 2023. Accessed August 2, 2023.
2. Fashner J, Gitu AC. Diagnosis and Treatment of Peptic Ulcer Disease and H. pylori Infection. *Am Fam Physician*. 2015;91(4):236 to 242
3. Chey WD, Leontiadis GI, Howden CW, Moss SF. Correction: ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. *Am J Gastroenterol*. 2018;113(7):1102. doi:10.1038/s41395-018-0132-6
4. Dore MP, Pes GM, Bassotti G, Usai-Satta P. Dyspepsia: When and how to test for Helicobacter pylori infection. *Gastroenterol Res Pract*. 2016;2016:8463614. doi:10.1155/2016/8463614
5. Talley NJ; American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. *Gastroenterology*. 2005;129(5):1753 to 1755. doi:10.1053/j.gastro.2005.09.019
6. Wang YK, Kuo FC, Liu CJ, et al. Diagnosis of Helicobacter pylori infection: Current options and developments. *World J Gastroenterol*. 2015;21(40):11221 to 11235. doi:10.3748/wjg.v21.i40.11221
7. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. *Gastroenterology*. 2005;129(5):1756 to 1780. doi:10.1053/j.gastro.2005.09.020

8. Pourakbari B, Ghazi M, Mahmoudi S, et al. Diagnosis of *Helicobacter pylori* infection by invasive and noninvasive tests. *Braz J Microbiol.* 2013;44(3):795 to 798. Published 2013 Nov 15. doi:10.1590/S1517-83822013005000052
9. Wang YK, Kuo FC, Liu CJ, et al. Diagnosis of *Helicobacter pylori* infection: Current options and developments. *World J Gastroenterol.* 2015;21(40):11221 to 11235. doi:10.3748/wjg.v21.i40.11221
10. Girdalidze AM, Elisabedashvili GV, Sharvadze LG, Dzhorbenadze TA. *Georgian Med News.* 2013;(225):53 to 60.
11. Choosing Wisely: Do not request serology for *H. pylori* - Use the stool antigen or breath tests instead. American Society for Clinical Pathology. [https://www.ascp.org/content/learning/explore-books-and-journals#lab\\_med](https://www.ascp.org/content/learning/explore-books-and-journals#lab_med) Published February 21, 2014. Accessed August 2, 2023.
12. Pak K, Junga Z, Mertz A, Singla M. The Patterns and Associated Cost of Serologic Testing for *Helicobacter pylori* in the U.S. Military Health System [published correction appears in *Mil Med.* 2020 Dec 30;185(11-12):e2201]. *Mil Med.* 2020;185(9-10):e1417 to e1419. doi:10.1093/milmed/usaa141
13. Katelaris P, Hunt R. World Gastroenterology Organisation Global Guidelines. *Helicobacter pylori.* <https://www.worldgastroenterology.org/guidelines/helicobacter-pylori/helicobacter-pylori-english> Published 2010 (Updated 2021). Accessed August 2, 2023.
14. Dore MP, Pes GM. What Is New in *Helicobacter pylori* Diagnosis. An Overview. *J Clin Med.* 2021;10(10):2091. Published 2021 May 13. doi:10.3390/jcm10102091

### **North Carolina Guidance**

#### **Eligibility Requirements**

- a. An eligible beneficiary shall be enrolled in the NC Medicaid Program (Medicaid is NC Medicaid program, unless context clearly indicates otherwise);
- b. Provider(s) shall verify each Medicaid beneficiary's eligibility each time a service is rendered.
- c. The Medicaid beneficiary may have service restrictions due to their eligibility category that would make them ineligible for this service.

#### **EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age**

- a. 42 U.S.C. § 1396d(r) [1905(r) of the Social Security Act]  
Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) is a federal Medicaid requirement that requires the state Medicaid agency to cover services, products, or procedures for Medicaid beneficiary under 21 years of age if the service is medically necessary health care to correct or ameliorate a defect, physical or mental illness, or a condition [health problem] identified through a screening examination (includes any evaluation by a physician or other licensed practitioner).

This means EPSDT covers most of the medical or remedial care a child needs to improve or maintain his or her health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

**CLINICAL POLICY WNC.CP.142**  
**HELICOBACTER PYLORI SEROLOGY TESTING**



Medically necessary services will be provided in the most economic mode, as long as the treatment made available is similarly efficacious to the service requested by the beneficiary's physician, therapist, or other licensed practitioner; the determination process does not delay the delivery of the needed service; and the determination does not limit the beneficiary's right to a free choice of providers.

EPSDT does not require the state Medicaid agency to provide any service, product or procedure:

1. that is unsafe, ineffective, or experimental or investigational.
2. that is not medical in nature or not generally recognized as an accepted method of medical practice or treatment.

Service limitations on scope, amount, duration, frequency, location of service, and other specific criteria described in clinical coverage policies may be exceeded or may not apply as long as the provider's documentation shows that the requested service is medically necessary "to correct or ameliorate a defect, physical or mental illness, or a condition" [health problem]; that is, provider documentation shows how the service, product, or procedure meets all EPSDT criteria, including to correct or improve or maintain the beneficiary's health in the best condition possible, compensate for a health problem, prevent it from worsening, or prevent the development of additional health problems.

**EPSDT and Prior Approval Requirements**

1. If the service, product, or procedure requires prior approval, the fact that the beneficiary is under 21 years of age does NOT eliminate the requirement for prior approval.
2. **IMPORTANT ADDITIONAL INFORMATION** about EPSDT and prior approval is found in the *NCTracks Provider Claims and Billing Assistance Guide*, and on the EPSDT provider page. The Web addresses are specified below:

*NCTracks Provider Claims and Billing Assistance Guide:*

<https://www.nctracks.nc.gov/content/public/providers/provider-manuals.html>

*EPSDT provider page:* <https://medicaid.ncdhhs.gov/>

*Provider(s) Eligible to Bill for the Procedure, Product, or Service*

To be eligible to bill for the procedure, product, or service related to this policy, the provider(s) shall:

- a. meet Medicaid qualifications for participation;
- b. have a current and signed Department of Health and Human Services (DHHS) Provider Administrative Participation Agreement; and
- c. bill only for procedures, products, and services that are within the scope of their clinical practice, as defined by the appropriate licensing entity.

*Compliance*

Provider(s) shall comply with the following in effect at the time the service is rendered:

**CLINICAL POLICY WNC.CP.142**  
**HELICOBACTER PYLORI SEROLOGY TESTING**



- a. All applicable agreements, federal, state and local laws and regulations including the Health Insurance Portability and Accountability Act (HIPAA) and record retention requirements; and
- b. All NC Medicaid's clinical (medical) coverage policies, guidelines, policies, provider manuals, implementation updates, and bulletins published by the Centers for Medicare and Medicaid Services (CMS), DHHS, DHHS division(s) or fiscal contractor(s).

*Claims-Related Information*

Provider(s) shall comply with the NC Tracks Provider Claims and Billing Assistance Guide, Medicaid bulletins, fee schedules, NC Medicaid's clinical coverage policies and any other relevant documents for specific coverage and reimbursement for Medicaid:

- a. Claim Type - as applicable to the service provided:  
Professional (CMS-1500/837P transaction)  
Institutional (UB-04/837I transaction)  
Unless directed otherwise, Institutional Claims must be billed according to the National Uniform Billing Guidelines. All claims must comply with National Coding Guidelines.
- b. International Classification of Diseases and Related Health Problems, Tenth Revisions, Clinical Modification (ICD-10-CM) and Procedural Coding System (PCS) - Provider(s) shall report the ICD-10-CM and Procedural Coding System (PCS) to the highest level of specificity that supports medical necessity. Provider(s) shall use the current ICD-10 edition and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for code description, as it is no longer documented in the policy.
- c. Code(s) - Provider(s) shall report the most specific billing code that accurately and completely describes the procedure, product or service provided. Provider(s) shall use the Current Procedural Terminology (CPT), Health Care Procedure Coding System (HCPCS), and UB-04 Data Specifications Manual (for a complete listing of valid revenue codes) and any subsequent editions in effect at the time of service. Provider(s) shall refer to the applicable edition for the code description, as it is no longer documented in the policy. If no such specific CPT or HCPCS code exists, then the provider(s) shall report the procedure, product or service using the appropriate unlisted procedure or service code.

*Unlisted Procedure or Service*

CPT: The provider(s) shall refer to and comply with the Instructions for Use of the CPT Codebook, Unlisted Procedure or Service, and Special Report as documented in the current CPT in effect at the time of service.

HCPCS: The provider(s) shall refer to and comply with the Instructions For Use of HCPCS National Level II codes, Unlisted Procedure or Service and Special Report as documented in the current HCPCS edition in effect at the time of service

- d. Modifiers - Providers shall follow applicable modifier guidelines.
- e. Billing Units - Provider(s) shall report the appropriate code(s) used which determines the billing unit(s).
- f. Co-payments -  
For Medicaid refer to Medicaid State Plan:  
<https://medicaid.ncdhhs.gov/get-involved/nc-health-choice-state-plan>



**CLINICAL POLICY WNC.CP.142**  
**HELICOBACTER PYLORI SEROLOGY TESTING**



- g. Reimbursement - Provider(s) shall bill their usual and customary charges. For a schedule of rates, refer to: <https://medicaid.ncdhhs.gov/>.

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

**CLINICAL POLICY WNC.CP.142**  
**HELICOBACTER PYLORI SEROLOGY TESTING**

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.